Joint Webinar: iPROLEPSIS & CARE-IN-HEALTH

From Chronic Inflammation to Personalised Prevention: Understanding, Predicting and Acting on the Health-to-Disease Transition

Format: Online via Microsoft Teams

Register here: LINK

Date: Monday, 30 November 2026

Time: 13:00 – 15:30 CET

The webinar brings together researchers, healthcare professionals, digital health developers and patient representatives to explore chronic inflammation, disease prediction and personalised prevention through clinical evidence, biomarkers, AI and digital health tools.

Opening Session - Connecting the dots: two projects, one challenge of chronic inflammation | 13:00-13:10

Welcome, brief project introductions and webinar objectives.

Speakers:

- **iPROLEPSIS Project Officer (TBC)** - Welcome remarks (2min)
- **CARE-IN-HEALTH Project Officer (TBC)** - Welcome remarks (2 min)
- **Prof. Leontios Hadjileontiadis**, Aristotle University of Thessaloniki, Greece, iPROLEPSIS Project Coordinator – Introduction to iPROLEPSIS and webinar objectives (2 min)
- **Prof. Magnus Bäck**, INSERM, Nancy, France - Karolinska Institutet, Sweden and Coordinator of the CARE-IN-HEALTH project – Introduction to CARE-IN-HEALTH and shared perspectives (2 min)

Session 1 - Understanding the Health-to-Disease Transition: Inflammation and Disease Risk | 13:10-13:40

Inflammation in Psoriatic Arthritis (iPROLEPSIS) and Cardiovascular Disease (CARE-IN-HEALTH)

Speakers:

- **Prof. Laura Coates**, University of Oxford, Leader of iPROLEPSIS clinical studies, **"Psoriatic disease – a continuum of disease"** (12 min)
- **Prof. Magnus Bäck**, INSERM, Nancy, France - Karolinska Institutet, Sweden and Coordinator of the CARE-IN-HEALTH project [TBC] (12 min)

Q&A (5 min)

Session 2 - From Research Questions to Clinical Evidence: Clinical studies and validation | 13:40-14:10

- *Study design and validation; recruitment; ethics; participant burden, lessons learned and challenges*
- *How clinical studies support biomarker/model development and validation*

Speakers:

- **Prof. Laura Coates**, University of Oxford, Leader of iPROLEPSIS clinical studies, **"Clinical studies to develop digital biomarkers in psoriatic disease"** (12 min)
- **Jennifer Meessen**, IRFMN, Italy, Leader of CARE-IN-HEALTH clinical studies, **The Resolvin Trial: RESOLving INflammation through Diet for Health Randomized Controlled Trial**. (12 min)

Q&A (5 min)

Session 3 - From Multimodal Data and Biomarkers of Disease Transition to AI-Based Personalised Risk Prediction | 14:10-14:40

- *Multimodal biomarkers of disease transition: discovery, data integration and harmonisation.*
- *AI-based personalised risk prediction: model development, validation and current findings.*
- *Explainability and trustworthy AI: shared challenges and opportunities for collaboration and harmonisation*.

Speakers:

- **Ali Saad** (AINIGMA Technologies) and **Eleni Vasileiou** (AUTH), **From multimodal data to digital biomarkers and AI-based disease monitoring and prediction in psoriatic arthritis** (12 min)
- **Caroline Brorsson**, Glucore, Sweden, CARE-IN-HEALTH WP6 Leader, [TBC] (12 min)

Q&A (5 min)

Session 4: From Prediction to Personalised Prevention: Digital Health in Practice | 14:40-15:10

- *Translating risk predictions into personalised preventive actions and clinical decision support.*
- *Co-creation with patients and healthcare professionals to support usability and adoption.*
- *A practical patient journey or brief demonstration illustrating how the proposed tools could support patients and healthcare professionals.*
- *Clinical adoption, sustainability and exploitation of project outcomes.*

Speakers

- **Dimitris Karamitros**, WELLICS, iPROLEPSIS WP4 Leader: **Data collection, disease monitoring and management digital tools** (12 min)
- **Ines Mendes Pinto**, i3s, Portugal, WP-6 Leader in CARE-IN-HEALTH, "**Molecular Biosensing Technologies for Timely Diagnosis and Monitoring of Cardiovascular Diseases"** (12 min)

Q&A (5 min)

Closing Remarks - Lessons Learned and next steps | 15:10-15:30 (20 min)

Key messages and shared lessons from the two projects. Opportunities for joint follow-up, including methodological exchanges, dissemination activities and comparison of validation approaches.

Speakers:

- **Prof. Leontios Hadjileontiadis**, Aristotle University of Thessaloniki, Greece, iPROLEPSIS Project Coordinator
- **Prof. Magnus Bäck**, INSERM, Nancy, France - Karolinska Institutet, Sweden and Coordinator of the CARE-IN-HEALTH project

Final audience Q&A (10 min)

END OF WEBINAR | 15:30 CET